Rapport Therapeutics (RAPP) Share-based Compensation (2023 - 2026)

Rapport Therapeutics (RAPP) has 4 years of Share-based Compensation data on record, last reported at $7.0 million in Q1 2026.

  • On a quarterly basis, Share-based Compensation rose 72.35% to $7.0 million in Q1 2026 year-over-year; TTM through Mar 2026 was $3.8 million, a 70.1% decrease, with the full-year FY2025 number at $900000.0, down 91.21% from a year prior.
  • Share-based Compensation reached $7.0 million in Q1 2026 per RAPP's latest filing, up from -$12.3 million in the prior quarter.
  • Over the last five years, Share-based Compensation for RAPP hit a ceiling of $7.0 million in Q1 2026 and a floor of -$12.3 million in Q4 2025.
  • A 4-year average of $1.7 million and a median of $2.8 million in 2024 define the central range for Share-based Compensation.
  • Peak YoY movement for Share-based Compensation: skyrocketed 270.43% in 2024, then plummeted 482.29% in 2025.
  • Tracing RAPP's Share-based Compensation over 4 years: stood at $998000.0 in 2023, then surged by 221.44% to $3.2 million in 2024, then tumbled by 482.29% to -$12.3 million in 2025, then skyrocketed by 156.78% to $7.0 million in 2026.
  • Business Quant data shows Share-based Compensation for RAPP at $7.0 million in Q1 2026, -$12.3 million in Q4 2025, and $4.7 million in Q3 2025.